辅助唑来膦酸联合来曲唑及卵巢功能抑制治疗绝经前乳腺癌:HOBOE 3期随机试验
HOBOE 3期随机试验纳入1065例激素受体阳性绝经前早期乳腺癌患者,均用曲普瑞林抑制卵巢功能,随机分配至他莫昔芬、来曲唑或唑来膦酸联合来曲唑辅助内分泌治疗5年。中位随访64个月,5年无病率他莫昔芬组85.4%、来曲唑组93.2%、唑来膦酸联合来曲唑组93.3%(总体P=0.008);唑来膦酸联合来曲唑较他莫昔芬显著改善无病生存(HR 0.52,95%CI 0.34-0.80,P=0.003),但依从性更差、毒性更高。
要点
- 唑来膦酸联合来曲唑较他莫昔芬显著改善无病生存,HR 0.52(95%CI 0.34-0.80,P=0.003)。
- 来曲唑较他莫昔芬无病生存无显著差异,HR 0.72(95%CI 0.48-1.07,P=0.06)。
- 唑来膦酸联合来曲唑组因毒性或拒绝停药比例16.6%,3-4级副作用9.1%。
核心结论
- HOBOE研究显示,在接受曲普瑞林卵巢功能抑制的绝经前早期乳腺癌患者中,唑来膦酸联合来曲唑较他莫昔芬显著改善无病生存,但依从性更差、毒性更高。
研究设计与样本
- 3期随机试验纳入1065例激素受体阳性绝经前早期乳腺癌患者,均接受曲普瑞林抑制卵巢功能,按1:1:1随机分配至他莫昔芬、来曲唑或唑来膦酸联合来曲唑辅助内分泌治疗5年。
主要发现
- 中位随访64个月、报告134例事件,5年无病率他莫昔芬组85.4%、来曲唑组93.2%、唑来膦酸联合来曲唑组93.3%(总体P=0.008)。
- 无病生存事件风险比:唑来膦酸联合来曲唑较他莫昔芬HR 0.52(95%CI 0.34-0.80,P=0.003);来曲唑较他莫昔芬HR 0.72(95%CI 0.48-1.07,P=0.06);唑来膦酸联合来曲唑较来曲唑HR 0.70(95%CI 0.44-1.12,P=0.22)。
- 报告36例死亡,总生存无显著差异(P=0.14)。
- 因毒性或拒绝停药比例:他莫昔芬组7.3%、来曲唑组7.3%、唑来膦酸联合来曲唑组16.6%;安全性人群中3-4级副作用分别报告于4.2%、6.9%和9.1%的患者。
临床怎么用
- 作者结论认为,在接受曲普瑞林卵巢功能抑制的绝经前早期乳腺癌患者中,唑来膦酸联合来曲唑较他莫昔芬显著改善无病生存,但依从性更差、毒性更高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of the study is to analyse whether letrozole (L) and zoledronic acid plus L (ZL) are more effective than tamoxifen (T) as adjuvant endocrine treatment of premenopausal patients with breast cancer with hormone receptor-positive (HR+) tumours. PATIENTS AND METHODS: In a phase 3 trial, 1065 premenopausal patients with HR + early breast cancer received triptorelin to suppress ovarian function and were randomly assigned (1:1:1) to adjuvant T, L or ZL for 5 years. Cancer recurrence, second breast or non-breast cancer and death were considered events for the intention-to-treat disease-free survival (DFS) analysis. RESULTS: With a 64-month median follow-up and 134 reported events, the disease-free rate at 5 years was 85.4%, 93.2% and 93.3% with T, L and ZL, respectively (overall P = 0.008). The hazard ratio for a DFS event was 0.52 (95% confidence interval [CI], 0.34 to 0.80; P = 0.003) with ZL vs T, 0.72 (95% CI, 0.48 to 1.07; P = 0.06) with L vs T and 0.70 (95% CI, 0.44 to 1.12; P = 0.22) with ZL vs L. With 36 deaths, there was no significant difference in overall survival (P = 0.14). Treatment was stopped for toxicity or refusal in 7.3%, 7.3% and 16.6% patients, and in the safety population, grade 3-4 side-effects were reported in 4.2%, 6.9% and 9.1% patients treated with T, L or ZL, respectively. CONCLUSION: HOBOE study shows that in premenopausal patients with early breast cancer undergoing ovarian function suppression with triptorelin, ZL significantly improves DFS, while worsening compliance and toxicity, as compared with T. (NCT00412022).
引用
- Perrone F, De Laurentiis M, De Placido S, et al. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. Eur J Cancer. 2019. PMID: 31164265. doi:10.1016/j.ejca.2019.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。